Alyeska Investment Group
FTH

Alyeska Investment Group’s Faeth Therapeutics FTH Stock Holding History

Alyeska Investment Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$390K – 785
2021
Q2 		$390K Buy
+2,000
New +$494K ﹤0.01% 663

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Alyeska Investment Group's FTH Position: Q3 2021 in Review

Alyeska Investment Group sold out of Faeth Therapeutics (FTH) in Q3 2021, closing a stake of 2,000 shares — an estimated $390K sold.

Alyeska Investment Group first reported a position in FTH in Q2 2021 and held it in 1 quarter. The position peaked at $390K in Q2 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q3 2021.

  • Alyeska Investment Group reported no remaining Faeth Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 2,000 Faeth Therapeutics shares in Q3 2021, an estimated $390K.
  • Alyeska Investment Group first reported a position in Faeth Therapeutics in Q2 2021 and held it in 1 quarter.
  • Alyeska Investment Group's Faeth Therapeutics position peaked at $390K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.